KYOTO HEART Study: valsartan and morbidity and mortality reduction in uncontrolled hypertensive patients with high cardiovascular risks

Valsartan add-on treatment to improve blood pressure control prevents more cardiovascular events than conventional non-ARB treatment in high-risk hypertensive patients. This data come from a multicenter randomized open blinded clinical study KYOTO, on more than 3000 patients followed for about 3 years...

http://eurheartj.oxfordjournals.org